

# Spiros Linardopoulos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5554255/publications.pdf>

Version: 2024-02-01

49  
papers

2,664  
citations

201674

27  
h-index

214800

47  
g-index

49  
all docs

49  
docs citations

49  
times ranked

4275  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. <i>Nature Genetics</i> , 2003, 34, 403-412.	21.4	310
2	Aurora Kinase Inhibitors: Current Status and Outlook. <i>Frontiers in Oncology</i> , 2015, 5, 278.	2.8	221
3	Aurora B Overexpression Associates with the Thyroid Carcinoma Undifferentiated Phenotype and Is Required for Thyroid Carcinoma Cell Proliferation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 928-935.	3.6	184
4	Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation. <i>Prostate</i> , 2006, 66, 326-333.	2.3	138
5	Functional Viability Profiles of Breast Cancer. <i>Cancer Discovery</i> , 2011, 1, 260-273.	9.4	134
6	Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. <i>Leukemia</i> , 2012, 26, 1462-1470.	7.2	105
7	Aurora-A Regulation of Nuclear Factor- $\kappa$ B Signaling by Phosphorylation of I $\kappa$ B $\beta$ . <i>Cancer Research</i> , 2007, 67, 1689-1695.	0.9	92
8	Imidazo[4,5- <i>b</i> ]pyridine Derivatives As Inhibitors of Aurora Kinases: Lead Optimization Studies toward the Identification of an Orally Bioavailable Preclinical Development Candidate. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 5213-5228.	6.4	80
9	The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2115-2123.	4.1	79
10	E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. <i>Cancer Discovery</i> , 2018, 8, 498-515.	9.4	79
11	Hit generation and exploration: Imidazo[4,5- <i>b</i> ]pyridine derivatives as inhibitors of Aurora kinases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 6567-6571.	2.2	78
12	Structure-Based Design of Orally Bioavailable 1 <i>H</i> -Pyrrolo[3,2- <i>c</i> ]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1). <i>Journal of Medicinal Chemistry</i> , 2013, 56, 10045-10065.	6.4	72
13	Aurora Isoform Selectivity: Design and Synthesis of Imidazo[4,5- <i>b</i> ]pyridine Derivatives as Highly Selective Inhibitors of Aurora-A Kinase in Cells. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9122-9135.	6.4	70
14	APC/C is an essential regulator of centrosome clustering. <i>Nature Communications</i> , 2014, 5, 3686.	12.8	70
15	Aurora kinase inhibition downregulates NF- $\kappa$ B and sensitises tumour cells to chemotherapeutic agents. <i>Biochemical and Biophysical Research Communications</i> , 2007, 352, 220-225.	2.1	66
16	Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 3147-3157.	4.1	65
17	Tumour selective targeting of cell cycle kinases for cancer treatment. <i>Current Opinion in Pharmacology</i> , 2013, 13, 529-535.	3.5	65
18	PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. <i>Modern Pathology</i> , 2010, 23, 1334-1345.	5.5	61

#	ARTICLE	IF	CITATIONS
19	Optimization of Imidazo[4,5- <i>b</i> ]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 8721-8734.	6.4	61
20	Aurora-expressing tumour cells are deficient for homology-directed DNA double strand break repair and sensitive to PARP inhibition. <i>EMBO Molecular Medicine</i> , 2010, 2, 130-142.	6.9	60
21	The Cyclin-Dependent Kinase Inhibitor Seliciclib (R-roscovitine; CYC202) Decreases the Expression of Mitotic Control Genes and Prevents Entry into Mitosis. <i>Cell Cycle</i> , 2007, 6, 3114-3131.	2.6	59
22	Aurora A Kinase Regulates Mammary Epithelial Cell Fate by Determining Mitotic Spindle Orientation in a Notch-Dependent Manner. <i>Cell Reports</i> , 2013, 4, 110-123.	6.4	59
23	New therapeutic perspectives in <i>CCDC6</i> deficient lung cancer cells. <i>International Journal of Cancer</i> , 2015, 136, 2146-2157.	5.1	41
24	A Cancer-associated Aurora A Mutant Is Mislocalized and Misregulated Due to Loss of Interaction with TPX2. <i>Journal of Biological Chemistry</i> , 2009, 284, 33177-33184.	3.4	40
25	Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer. <i>Nature Communications</i> , 2018, 9, 1044.	12.8	39
26	Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2410-2421.	4.1	32
27	Structure-based design of imidazo[1,2- <i>a</i> ]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5988-5993.	2.2	30
28	Rapid Discovery of Pyrido[3,4- <i>d</i> ]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 3671-3688.	6.4	29
29	Naturally Occurring Mutations in the <i>MPS1</i> Gene Predispose Cells to Kinase Inhibitor Drug Resistance. <i>Cancer Research</i> , 2015, 75, 3340-3354.	0.9	27
30	Aurora B prevents premature removal of spindle assembly checkpoint proteins from the kinetochore: A key role for Aurora B in mitosis. <i>Oncotarget</i> , 2018, 9, 19525-19542.	1.8	27
31	Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- <i>d</i> ]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate <i>N</i> <sup>2</sup> -(2-Ethoxy-4-(4-methyl-4- <i>H</i> -1,2,4-triazol-3-yl)phenyl)-6-methyl- <i>N</i> <sup>8</sup> -neopentylpyrido[3,4- <i>d</i> ]pyrimidin-2(1 <i>H</i> )-one (BOS172722). <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8226-8240.	6.4	24
32	High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1696-1707.	4.1	24
33	Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy. <i>British Journal of Cancer</i> , 2017, 116, 1166-1176.	6.4	23
34	High-Throughput Screening Assay for Identification of Small Molecule Inhibitors of Aurora2/STK15 Kinase. <i>Journal of Biomolecular Screening</i> , 2004, 9, 391-397.	2.6	18
35	Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736. <i>Blood Advances</i> , 2020, 4, 1478-1491.	5.2	15
36	RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses. <i>British Journal of Cancer</i> , 2017, 117, 954-964.	6.4	14

#	ARTICLE	IF	CITATIONS
37	7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituent. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4203-4209.	2.2	13
38	CCT245718, a dual FLT3/Aurora A inhibitor overcomes D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells. <i>British Journal of Cancer</i> , 2021, 125, 966-974.	6.4	11
39	Aurora Kinase Inhibition: A New Light in the Sky?. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5186-5188.	6.4	9
40	The N-terminal domain of the Aurora-A Phe-31 variant encodes an E3 ubiquitin ligase and mediates ubiquitination of I $\beta$ B $\beta$ . <i>Human Molecular Genetics</i> , 2006, 15, 3343-3350.	2.9	7
41	Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia. <i>Leukemia Research</i> , 2011, 35, 1273-1275.	0.8	6
42	Integration of RNAi and Small Molecule Screens to Identify Targets for Drug Development. <i>Methods in Molecular Biology</i> , 2013, 986, 97-104.	0.9	6
43	Targeting the PPM1D phenotype; 2,4-bisarylthiazoles cause highly selective apoptosis in PPM1D amplified cell-lines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3469-3474.	2.2	5
44	Sensitization of (colon) cancer cells to death receptor related therapies. <i>Cancer Biology and Therapy</i> , 2012, 13, 458-466.	3.4	4
45	Aurora-A kinase regulates NF-kappaB activity: lessons from combination studies. <i>Journal of B U on</i> , 2007, 12 Suppl 1, S67-70.	0.4	4
46	Metabolism of the dual FLT-3/Aurora kinase inhibitor CCT241736 in preclinical and human in vitro models: Implication for the choice of toxicology species. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 139, 104899.	4.0	3
47	Abstract B74: The dual FLT3-Aurora inhibitor CCT241736 overcomes resistance to selective FLT3 inhibition driven by FLT3 ligand and FLT3 point mutations in acute myeloid leukemia.. , 2011, , .		3
48	Integration of RNAi and Small Molecule Screens to Identify Targets for Drug Development. <i>Methods in Molecular Biology</i> , 2019, 1953, 33-42.	0.9	2
49	Abstract 889: Integration of centrosome-associated and kinase-related screens to identify centrosome amplification-related synthetic lethal interactions. , 2012, , .		0